UNLIMITED TURBO SHORT - MODERNA | Real-time Bid/Ask 17:01:10 05/06/2024 BST | ||
| 13.52 EUR / 13.54 EUR | -3.77% |
|
| Current month | -1.68% | ||
| 1 month | -12.78% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
MODERNA, INC.
Latest news about MODERNA, INC.
More news
| Date | Price | Change |
|---|---|---|
| 05/06/24 | 13.52 | -3.84% |
| 04/06/24 | 14.06 | +2.11% |
| 03/06/24 | 13.77 | -3.71% |
| 31/05/24 | 14.3 | +5.54% |
| 30/05/24 | 13.55 | -2.45% |
Delayed Quote Börse Stuttgart
Last update June 05, 2024 at 05:00 pm
More quotesStatic data
| Product type | Knock-Out without Stop Loss |
|---|---|
| Buy / Sell | PUT |
| Underlying | MODERNA, INC. |
| Issuer | 
BNP Paribas
|
| WKN | PE6RJX |
| ISIN | DE000PE6RJX0 |
| Date issued | 15/12/2022 |
| Strike | 295.9 $ |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 9.35 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 22.03 € |
|---|---|
| Lowest since issue | 8.51 € |
| Spread | 0.02 € |
| Spread % | 0.15% |
Company Profile
Moderna, Inc. is a biotechnology company specialized in research and development of therapeutics and vaccines for cancer, infectious, autoimmune and cardiovascular diseases. Net sales break down by type of revenue as follows:
- revenue from product sales (95.7%) ;
- revenues from grants (4%);
- revenues from collaboration agreements (0.3%).
At the end of 2021, the group possessed a portfolio of 15 products in clinical development, of which 3 in phase III, 8 in phase II and 4 in phase I, and 12 products in preclinical development.
Net sales are distributed geographically as follows: the United States (33.4%), Europe (37.1%) and other (29.5%).
Sector
-
Consensus: Moderna, Inc.
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
25
Last Close Price
145.3
USD
Average target price
142.8
USD
Spread / Average Target
-1.74%
- Stock Market
- Certificates
- Certificat